Increased OATP1B3 expression in prostate cancer can be induced by ADT, which provides a clue for sequential therapy design: Upregulated tumor SLCO expression following ADT could potentially enhance the uptake of chemotherapeutic drugs like taxanes and improve treatment response.114. The gene discussed is SLCO1B3; the disease is prostate carcinoma.